Erythropoietin reduces experimental autoimmune encephalomyelitis severity via neuroprotective mechanisms

BACKGROUND: Treatment with erythropoietin (Epo) in experimental autoimmune encephalomyelitis (EAE), the rodent model of multiple sclerosis (MS), has consistently been shown to ameliorate disease progression and improve overall outcome. The effect has been attributed to modulation of the immune respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Moransard, M., Bednar, M., Frei, K., Gassmann, M., Ogunshola, O. O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640948/
https://www.ncbi.nlm.nih.gov/pubmed/29029628
http://dx.doi.org/10.1186/s12974-017-0976-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640948/
https://www.ncbi.nlm.nih.gov/pubmed/29029628
http://dx.doi.org/10.1186/s12974-017-0976-5

Ejemplares similares